Oslo, Norway, 8 November 2023 - Photocure ASA today reported Hexvix®/Cysview® revenues of NOK 107.3 million in the third quarter of 2023 , and an EBITDA of NOK 3.3 million for the company..
/PRNewswire/ Photocure ASA (OSE:PHO) today reported Hexvix®/Cysview® revenues of NOK 107.3 million in the third quarter of 2023 (Q3 2022: NOK 96.9 million),.
Photocure: Positive Results for Hexvix Phase III Clinical Trial in China Presented at the SIU 2023 Congress finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Positive Results for Hexvix Phase III Clinical Trial in China Presented at the SIU 2023 Congress streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Press Release - Oslo, Norway, October 7, 2023: Photocure ASA , the Bladder Cancer Company, announces that its partner Asieris Pharmaceuticals has communicated its plan today to unveil the first.